背景:Dolomiaeacostus(Falc。),以前的雪莲(Falc。)嘴唇。,一种阿育吠陀药用植物,长期以来,由于其多方面的治疗特性,在不同的土著医学系统中得到了认可和利用,包括消炎药,驱风,祛痰药,抗关节炎,防腐剂,壮阳药,止痛药,和抗糖尿病作用。
目的:本研究探讨了山竹根作为抗糖尿病药物的潜在作用和潜在机制。此外,酚类和类黄酮化合物的定量,占主导地位的提取物,特别感兴趣的是为了阐明它们对观察到的效果的贡献。
方法:采用高效液相色谱/电喷雾串联质谱(HPLC-ESI-MS/MS)对马蹄草根水提物(DCA)和马蹄草根乙醇提物(DCE)的化学成分进行分析。此外,DCE及其各自部分以及DCA对α-淀粉酶的抑制潜力,α-葡萄糖苷酶,和脂肪酶进行了评估。随后,使用已建立的链脲佐菌素(STZ)诱导的糖尿病动物模型评估DCA和DCE提取物的功效;这涉及以200和400mg/kgbwt的剂量施用提取物。并将它们与阳性对照(格列本脲(Glib.)为0.6毫克/千克重量重量。).诱导糖尿病后(阴性对照除外),所有动物连续接受21天口服治疗,然后收集大鼠血清以评估各种参数,包括,血糖和血脂,肝肾功能,抗氧化活性,糖酵解,和糖异生途径。
结果:HPLC-ESI-MS/MS结果表明,异绿原酸A(8393.64μg/g)和绿原酸(6532.65μg/g)是DCE和DCA中的主要化合物。分别。两种提取物均表现出显着的抗糖尿病特性,它们调节血糖和血脂特征的能力证明了这一点(葡萄糖,胰岛素,HBA1C;HDL,TC,TG),肝酶(ALT,ALP,AST),肾功能(尿素,肌酐,尿酸),氧化应激生物标志物(MDA),抗氧化酶(CAT,GSH,SOD),以及糖酵解(葡萄糖激酶)和糖异生(G-6-P,FBP1)途径。
结论:此外,D.costus提取物的给药显著减轻STZ诱导的糖尿病性高血糖症。这些结果可以归因于,至少部分地,几种具有有效抗氧化和抗炎活性的多酚化合物的存在。
BACKGROUND: Dolomiaea costus (Falc.), formerly Saussurea costus (Falc.) Lipsch., an ayurvedic medicinal plant, has long been recognized and utilized in diverse indigenous systems of medicine for its multifaceted therapeutic properties, including anti-inflammatory, carminative, expectorant, antiarthritic, antiseptic, aphrodisiac, anodyne, and antidiabetic effects.
OBJECTIVE: The potential and underlying mechanisms of D. costus root as an antidiabetic agent were investigated in this study. Additionally, the quantification of phenolic and flavonoid compounds, which dominate the extracts, was of particular interest in order to elucidate their contribution to the observed effects.
METHODS: High-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) was employed to analyze the chemical constituents in D. costus root aqueous extract (DCA) and D. costus root ethanolic extract (DCE). Furthermore, the inhibitory potentials of DCE and its respective fractions as well as DCA against α-amylase, α-glucosidase, and lipase enzymes were assessed. Subsequently, the efficacy of DCA and DCE extracts was evaluated using an established streptozotocin (STZ)-induced diabetic animal model; this involved administering the extracts at doses of 200 and 400 mg/kg bwt. and comparing them with a positive control (glibenclamide (Glib.) at 0.6 mg/kg bwt.). After induction of diabetes (except for negative control), all animals received the treatments orally for 21 days consecutively, followed by the collection of rat serum to assess various parameters including, glycemic and lipid profiles, liver and kidney functions, antioxidant activity, glycolysis, and gluconeogenesis pathways.
RESULTS: The results of HPLC-ESI-MS/MS revealed that isochlorogenic acid A (8393.64 μg/g) and chlorogenic acid (6532.65 μg/g) were the predominant compounds in DCE and DCA, respectively. Both extracts exhibited notable antidiabetic properties, as evidenced by their ability to regulate blood glycemic and lipid profiles (glucose, insulin, HBA1C; HDL, TC, TGs), liver enzymes (ALT, ALP, AST), kidney function (urea, creatinine, uric acid), oxidative stress biomarkers (MDA), antioxidant enzymes (CAT, GSH, SOD), as well as glycolysis (glucokinase) and gluconeogenesis (G-6-P, FBP1) pathways.
CONCLUSIONS: Furthermore, the administration of D. costus extracts significantly mitigated STZ-induced diabetic hyperglycemia. These results can be attributed, at least partially, to the presence of several polyphenolic compounds with potent antioxidant and anti-inflammatory activities.